Delmitide (acetate)

Delmitide (RDP58) acetate is an orally active d-isomer decapeptide with potent anti-inflammatory activity. Delmitide acetate inhibits production of TNF-α, IFN-γ, and interleukin (IL) -12, and up-regulates heme oxygenase 1 activity. Delmitide acetate can be used for the research of ulcerative colitis[1][2].

Product Specifications

CAS Number

[501019-16-5]

Product Name Alternative

RDP-58 (acetate)

UNSPSC

12352209

Target

IFNAR; Reactive Oxygen Species (ROS) ; TNF Receptor

Type

Peptides

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/delmitide-acetate.html

Purity

99.22

Solubility

10 mM in DMSO

Smiles

N=C(N)NCCC[C@@H](N)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCNC(N)=N)C(N[C@H](CCCC)C(N[C@H](CCCC)C(N[C@H](CCCC)C(NCC(N[C@@H](C(N)=O)CC1=CC=C(O)C=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O

Molecular Formula

C59H105N17O11.C2H4O2

Molecular Weight

1288.62

References & Citations

[1]Arthur Kaser, et al. Novel therapeutic targets in the treatment of IBD. Kaser, Arthur; Tilg, Herbert (2008) . Expert Opinion on Therapeutic Targets, 12 (5), 553–563.|[2]Jingsong Zhao, et al. Oral RDP58 allows CPT-11 dose intensification for enhanced tumor response by decreasing gastrointestinal toxicity. Clin Cancer Res. 2004 Apr 15;10 (8) :2851-9.